Targeted protein degradation never had it so good. In July, Pfizer paid Arvinas $650 million
up front, plus a $350-million equity investment, to jointly develop a PROTAC degrader, now …

Overexpression of prosurvival proteins such as Bcl-2 and Bcl-XL has been correlated with
tumorigenesis and resistance to chemotherapy, and thus, the development of antagonists of …

Overexpression of anti-apoptotic BCL-2 family members is a hallmark of many lymphoid
malignancies, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma …

The B‐cell lymphoma 2 (BCL 2) family of proteins comprise key regulators of apoptosis and
are implicated in the pathogenesis of many malignancies, including lymphomas and …

Although proteolysis targeting chimeras (PROTACs) have become promising therapeutic
modalities, important concerns exist about the potential toxicity of the approach owing to …

Protein degradation mediated by the proteolysis-targeting chimera (PROTAC) has emerged
as an efficient strategy to accurately control intracellular protein levels. However, the …

Deregulated Myc expression drives many human cancers, including Burkitt's lymphoma and
a highly aggressive subset of diffuse large cell lymphomas. Myc-driven tumors often display …

Effective and sustained inhibition of non-enzymatic oncogenic driver proteins is a major
pharmacological challenge. The clinical success of thalidomide analogues demonstrates …

Molecularly targeted cancer therapies substantially improve patient outcomes, although the
durability of their effectiveness can be limited. Resistance to these therapies is often related …

Purpose: To investigate the roles of BCL2, MCL1, and BCL-XL in the survival of diffuse large
B-cell lymphoma (DLBCL). Experimental designs: Immunohistochemical analysis of 105 …